174 related articles for article (PubMed ID: 21586205)
1. Treating polyarteritis nodosa: current state of the art.
de Menthon M; Mahr A
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S110-6. PubMed ID: 21586205
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polyarteritis nodosa and Churg-Strauss syndrome: indications of plasma exchanges.
Guillevin L; Lhote F
Transfus Sci; 1994 Dec; 15(4):371-88. PubMed ID: 10155556
[TBL] [Abstract][Full Text] [Related]
3. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years.
Guillevin L; Lhote F; Jarrousse B; Fain O
Ann Med Interne (Paris); 1992; 143(6):405-16. PubMed ID: 1363508
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.
Guillevin L; Lhote F; Gayraud M; Cohen P; Jarrousse B; Lortholary O; Thibult N; Casassus P
Medicine (Baltimore); 1996 Jan; 75(1):17-28. PubMed ID: 8569467
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients.
Guillevin L; Lhote F; Cohen P; Jarrousse B; Lortholary O; Généreau T; Léon A; Bussel A
Arthritis Rheum; 1995 Nov; 38(11):1638-45. PubMed ID: 7488285
[TBL] [Abstract][Full Text] [Related]
6. Polyarteritis nodosa: A contemporary overview.
De Virgilio A; Greco A; Magliulo G; Gallo A; Ruoppolo G; Conte M; Martellucci S; de Vincentiis M
Autoimmun Rev; 2016 Jun; 15(6):564-70. PubMed ID: 26884100
[TBL] [Abstract][Full Text] [Related]
7. Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa.
Hočevar A; Tomšič M; Perdan Pirkmajer K
Curr Rheumatol Rep; 2021 Feb; 23(3):14. PubMed ID: 33569653
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous immunoglobulins].
Machet L; Vincent O; Machet MC; Barruet K; Vaillant L; Lorette G
Ann Dermatol Venereol; 1995; 122(11-12):769-72. PubMed ID: 8729821
[TBL] [Abstract][Full Text] [Related]
9. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.
Gayraud M; Guillevin L; le Toumelin P; Cohen P; Lhote F; Casassus P; Jarrousse B;
Arthritis Rheum; 2001 Mar; 44(3):666-75. PubMed ID: 11263782
[TBL] [Abstract][Full Text] [Related]
10. [Polyarteritis nodosa: differential diagnostics and therapy].
Schirmer JH; Holl-Ulrich K; Moosig F
Z Rheumatol; 2014 Dec; 73(10):917-26; quiz 926-7. PubMed ID: 25391370
[TBL] [Abstract][Full Text] [Related]
11. [A case of PAN with positive Hbs Ag cured by immunosuppressive and antiviral therapies: a case report].
Choucair J; Hajj G; Abi Karam G
J Med Liban; 2007; 55(1):50-2. PubMed ID: 17489308
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.
Guillevin L; Mahr A; Callard P; Godmer P; Pagnoux C; Leray E; Cohen P;
Medicine (Baltimore); 2005 Sep; 84(5):313-322. PubMed ID: 16148731
[TBL] [Abstract][Full Text] [Related]
13. Granulomatous Vasculitis.
Sharma A; Dogra S; Sharma K
Dermatol Clin; 2015 Jul; 33(3):475-87. PubMed ID: 26143427
[TBL] [Abstract][Full Text] [Related]
14. Polyarteritis nodosa.
Forbess L; Bannykh S
Rheum Dis Clin North Am; 2015; 41(1):33-46, vii. PubMed ID: 25399938
[TBL] [Abstract][Full Text] [Related]
15. Polyarteritis nodosa.
Stone JH
JAMA; 2002 Oct; 288(13):1632-9. PubMed ID: 12350194
[TBL] [Abstract][Full Text] [Related]
16. [ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure].
Reinhold-Keller E; Tatsis E; Gross WL
Z Rheumatol; 1995; 54(5):303-9. PubMed ID: 8578886
[TBL] [Abstract][Full Text] [Related]
17. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
Chung SA; Gorelik M; Langford CA; Maz M; Abril A; Guyatt G; Archer AM; Conn DL; Full KA; Grayson PC; Ibarra MF; Imundo LF; Kim S; Merkel PA; Rhee RL; Seo P; Stone JH; Sule S; Sundel RP; Vitobaldi OI; Warner A; Byram K; Dua AB; Husainat N; James KE; Kalot M; Lin YC; Springer JM; Turgunbaev M; Villa-Forte A; Turner AS; Mustafa RA
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1061-1070. PubMed ID: 34235889
[TBL] [Abstract][Full Text] [Related]
18. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years.
Eleftheriou D; Dillon MJ; Tullus K; Marks SD; Pilkington CA; Roebuck DJ; Klein NJ; Brogan PA
Arthritis Rheum; 2013 Sep; 65(9):2476-85. PubMed ID: 23754739
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and classification of polyarteritis nodosa.
Hernández-Rodríguez J; Alba MA; Prieto-González S; Cid MC
J Autoimmun; 2014; 48-49():84-9. PubMed ID: 24485157
[TBL] [Abstract][Full Text] [Related]
20. Reversible bilateral hydronephrosis without obstruction in hepatitis B-associated polyarteritis nodosa.
Casserly LF; Reddy SM; Rennke HG; Carpinito GA; Levine JS
Am J Kidney Dis; 1999 Sep; 34(3):e11. PubMed ID: 10471757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
